Vicebio closes $100m financing round to advance multivalent vaccine technology
The series B fundraising will support the clinical development of next-generation multivalent vaccines against respiratory viruses.
Archives for September 24, 2024
UCB and Biogen announce positive Phase 3 results for dapirolizumab pegol in systemic lupus erythematosus
UCB and Biogen revealed that their Phase 3 study testing dapirolizumab pegol in people with systemic lupus erythematosus met the primary and secondary endpoints.